Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03788434 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Study of VE303 for Prevention of Recurrent Clostridioides Difficile Infection
A Phase 2 study, sponsored by Vedanta Biosciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 79
- Enrollment target
NCT03788434 is a Phase 2 study that has completed, run by Vedanta Biosciences. The registered enrollment target is 79 participants.
The verdict
NCT03788434, a Phase 2 study, has completed, sponsored by Vedanta Biosciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 79 participants
- Enrollment target
Study Summary
This study evaluated the safety and efficacy of VE303 for participants with primary C. difficile infection (pCDI) at high risk for recurrence or subjects with recurrent C. difficile infections (rCDI).
Interventions
- DRUG Placebo
- DRUG VE303
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 79 participants |
| Start Date | 2019-02-08 |
| Est. Completion | 2021-09-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03788434
The ClinicalTrials.gov registry entry for NCT03788434 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 79 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vedanta Biosciences, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03788434 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03788434 about?
NCT03788434 is a clinical study titled "Phase 2 Study of VE303 for Prevention of Recurrent Clostridioides Difficile Infection". This study evaluated the safety and efficacy of VE303 for participants with primary C. difficile infection (pCDI) at high risk for recurrence or subjects with recurrent C. difficile infections (rCDI).
What is the current status of trial NCT03788434?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 79 participants. The study started on 2019-02-08. Estimated completion is 2021-09-15.
What interventions are being tested in trial NCT03788434?
The interventions under investigation include: Placebo (DRUG), VE303 (DRUG).
Who is sponsoring clinical trial NCT03788434?
This trial is sponsored by Vedanta Biosciences, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.